Pasadena, United States
Terray Therapeutics, founded in 2018, is an innovative biotechnology company dedicated to transforming small molecule drug discovery. Their slogan, "Everything small molecule drug discovery should be.", encapsulates their commitment to revolutionizing this space.
The company leverages a powerful platform integrating ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. This approach generates massive, precise datasets that enhance value with each iteration, promising improvements in speed, cost, and success rates for drug discovery.
Based in the United States, Terray Therapeutics has attracted notable investors such as Madrona, Two Sigma Ventures, and Maverick Capital. The latest investment, a $120.00M Series B round in October 2024, underscores strong investor confidence in their pioneering approach.
Optibrium